Cornerstone pharmaceuticals initiates phase 1 trial of cpi-613® (devimistat) in combination with chemoradiation for the treatment of advanced pancreatic cancer

Clinical program advancement represents key milestone for cornerstone underscoring its commitment to the development of lead compound, devimistat, in pancreatic cancer clinical program advancement represents key milestone for cornerstone underscoring its commitment to the development of lead compound, devimistat, in pancreatic cancer
RFL Ratings Summary
RFL Quant Ranking